Methamphetamine Dependence Clinical Trial
Official title:
Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine use has escalated in recent years. Methamphetamine use has also spread throughout the country. Although much information has been gathered on the treatment of cocaine abuse, very little information has been obtained on the treatment of methamphetamine abuse. One of the first steps in developing appropriate treatment is to examine the effects of stopping a particular substance's use on individuals abusing that substance. To date this has not been well studied for people abusing methamphetamine. The purpose of this study is to better understand and develop accurate ways of measuring symptoms associated with stopping the use of methamphetamine in people that are abusing methamphetamine. If the withdrawal symptoms are able to be effectively measured, this will help to develop treatments targeted at alleviating these symptoms. These symptoms are often associated with relapse to use of that substance.
The primary aim of this 4 week observational study is to examine and characterize the withdrawal symptoms experienced by methamphetamine abusers who are recently abstinent from methamphetamine. The period of drug or substance withdrawal is often cited as the time during which risk of relapse use of that substance is very high. Therefore it is highly important to characterize specifically the withdrawal syndrome associated with cessation of methamphetamine use. This study will demonstrate our ability to recruit and work with this methamphetamine dependent population. In addition it will allow for the collection of pilot data to assist in selecting appropriate assessment tools in a submission of an RO1 grant for well-controlled studies characterizing methamphetamine withdrawal. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01813656 -
An Study of Aripiprazole in the Treatment of Methamphetamine Dependence
|
Phase 4 | |
| Completed |
NCT00984360 -
Study of Naltrexone for Methamphetamine Addiction
|
Phase 2 | |
| Completed |
NCT01685463 -
Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving
|
N/A | |
| Completed |
NCT00569374 -
Safety and Tolerability of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
| Completed |
NCT01354470 -
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Active, not recruiting |
NCT01044238 -
Methylphenidate to Treat Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01215929 -
Studying Amphetamine Withdrawal in Humans
|
Phase 2 | |
| Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
| Completed |
NCT00227123 -
A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence
|
N/A | |
| Recruiting |
NCT02568878 -
Creatine for Depressed Male and Female Methamphetamine Users
|
Phase 3 | |
| Completed |
NCT01007539 -
Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence
|
Phase 3 | |
| Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT00687713 -
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT02058966 -
Pilot Study of Entacapone for Methamphetamine Abuse
|
Early Phase 1 | |
| Completed |
NCT00332605 -
N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01860807 -
Trial of Ibudilast for Methamphetamine Dependence
|
Phase 2 | |
| Terminated |
NCT01813643 -
A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis
|
Phase 4 |